Comparative Pharmacology
Head-to-head clinical analysis: METHADOSE versus TRAMADOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHADOSE versus TRAMADOL.
METHADOSE vs Tramadol
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day. For moderate to severe pain, 50-100 mg IV or IM every 4-6 hours; maximum 600 mg/day.
None Documented
None Documented
Clinical Note
moderateTramadol + Torasemide
"The risk or severity of adverse effects can be increased when Tramadol is combined with Torasemide."
Clinical Note
moderateTramadol + Etacrynic acid
"The risk or severity of adverse effects can be increased when Tramadol is combined with Etacrynic acid."
Clinical Note
moderateTramadol + Furosemide
"The risk or severity of adverse effects can be increased when Tramadol is combined with Furosemide."
Clinical Note
moderateTramadol + Bumetanide
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Terminal elimination half-life: approximately 6.3 hours (range 5-9 hours) for tramadol; active metabolite M1 has half-life ~7-9 hours. Clinically, dosing interval is typically every 4-6 hours.
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Primarily renal (90%): ~30% as unchanged drug, ~60% as metabolites. Biliary/fecal: ~10%.
Category C
Category D/X
Opioid Agonist
Opioid Agonist
"The risk or severity of adverse effects can be increased when Tramadol is combined with Bumetanide."